Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Dexcom (DXCM) over the last 17 years, with Q4 2025 value amounting to -$1.5 billion.

  • Dexcom's Cash from Financing Activities fell 9503750.0% to -$1.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.7 billion, marking a year-over-year decrease of 12950.46%. This contributed to the annual value of -$1.7 billion for FY2025, which is 12950.46% down from last year.
  • Per Dexcom's latest filing, its Cash from Financing Activities stood at -$1.5 billion for Q4 2025, which was down 9503750.0% from -$175.0 million recorded in Q3 2025.
  • Dexcom's 5-year Cash from Financing Activities high stood at $939.5 million for Q2 2023, and its period low was -$1.5 billion during Q4 2025.
  • Its 5-year average for Cash from Financing Activities is -$164.1 million, with a median of -$1.2 million in 2022.
  • As far as peak fluctuations go, Dexcom's Cash from Financing Activities skyrocketed by 2194883.72% in 2023, and later crashed by 9503750.0% in 2025.
  • Quarter analysis of 5 years shows Dexcom's Cash from Financing Activities stood at -$800000.0 in 2021, then dropped by 25.0% to -$1.0 million in 2022, then crashed by 63090.0% to -$631.9 million in 2023, then surged by 99.75% to -$1.6 million in 2024, then plummeted by 95037.5% to -$1.5 billion in 2025.
  • Its Cash from Financing Activities was -$1.5 billion in Q4 2025, compared to -$175.0 million in Q3 2025 and -$1.7 million in Q2 2025.